Danny Gonnissen
Directeur/Bestuurslid bij PharmaFluidics NV
Oorsprong van het eerstegraads netwerk van Danny Gonnissen
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
QBIC Venture Partners BV
QBIC Venture Partners BV Investment ManagersFinance QBIC Venture Partners BVBA (QBIC Venture Partners) is a venture capital firm founded in 2012 by Marc Zabeau. The firm is headquartered in Belgium.
8
| Private Company | Investment Managers | 8 |
PharmaFluidics NV
PharmaFluidics NV Electronic Equipment/InstrumentsElectronic Technology Pharmafluidics NV develops micro chip liquid chromatography cartridges for analysis of complex biological samples. The company was founded by Wim De Malsche, Joeri Denayer, Gert Desme and Paul Godelieve Jacobs in 2010 and is headquartered in Ghent, Belgium.
8
| Subsidiary | Electronic Equipment/Instruments | 8 |
Newton Biocapital Partners SRL
Newton Biocapital Partners SRL Investment ManagersFinance Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre.
4
| Private Company | Investment Managers | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Danny Gonnissen via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
TIGENIX NV | Medical Specialties | Director/Board Member | |
MDXHEALTH SA | Medical Specialties | Director/Board Member Director/Board Member | |
D'IETEREN GROUP | Other Consumer Services | Director/Board Member | |
QUEST FOR GROWTH NV | Investment Managers | Director/Board Member Chief Investment Officer | |
Tibotec Virco NV
Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
CropDesign NV
CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member | |
Gimv Information & Communication Technology ICT
Gimv Information & Communication Technology ICT Investment ManagersFinance Gimv Information & Communication Technology ICT (Gimv-ICT) is the venture capital division of Belgium's Gimv NV (XB: GIMB), an investment firm founded in 1980. Based in Antwerp, the firm focuses on investing in high growth companies in the telecommunications, software and electronics industries. | Investment Managers | Corporate Officer/Principal | |
Ghent University | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
Université Libre de Bruxelles | College/University | Graduate Degree Corporate Officer/Principal | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Vrije Universiteit Brussel | College/University | Graduate Degree Masters Business Admin | |
MyCartis NV
MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director of Finance/CFO | |
UGent TechTransfer
UGent TechTransfer Investment ManagersFinance UGent TechTransfer is a venture capital firm, a subsidiary of Ghent University founded in 1999. UGent TechTransfer is headquartered in Zwijnaarde, Belgium. | Investment Managers | President | |
Biotechnological Enzymatic Catalyse NV
Biotechnological Enzymatic Catalyse NV Food: Major DiversifiedConsumer Non-Durables Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium. | Food: Major Diversified | Director/Board Member | |
Université Catholique de Louvain | College/University | Graduate Degree | |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Investment Managers | Private Equity Investor | |
Trinean NV
Trinean NV Electronic Equipment/InstrumentsElectronic Technology Trinean NV develops and produces nanoliter spectrophotometers and consumables. Its products include DropSense96, Xpose, and spectral content profiling. The firm covers both microfluidic structures and multi-channel spectrometry for microliter sample handling. The company was founded by Ronny Baeckstaele and Kris Naessens in 2006 and is headquartered in Gentbrugge, Belgium. | Electronic Equipment/Instruments | Director/Board Member Chief Executive Officer Director/Board Member | |
VOLUNTIS S.A. | Packaged Software | Director/Board Member | |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member | |
Maize Technologies International GmbH | Director/Board Member | ||
The Belgian Venture Capital & Private Equity Association
The Belgian Venture Capital & Private Equity Association Miscellaneous Commercial ServicesCommercial Services The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Peptisyntha, Inc. | Director/Board Member | ||
AQ Invest BV | Corporate Officer/Principal | ||
Vesalius Biocapital II Partners SARL | Founder | ||
Solvay Business School of Economics & Management | College/University | Undergraduate Degree Graduate Degree | |
Biogazelle NV
Biogazelle NV BiotechnologyHealth Technology Biogazelle NV is a research and development stage biotechnology firm. It specializes in ribonucleic acid for next generation diagnostics in the field of oncology and other diseases. The company was founded by Jan Hellemans and Jo Vandesompele in 2007 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member | |
Bioxodes SA
Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
UgenTec NV
UgenTec NV Packaged SoftwareTechnology Services UgenTec NV develops laboratory software. The firm delivers an independent diagnostic platform to help molecular labs with DNA (PCR) analyses. The company was founded by Tom Martens and Wouter Uten on April 30, 2014 and is headquartered in Hasselt, Belgium. | Packaged Software | Director/Board Member | |
Bio-Sourcing SA
Bio-Sourcing SA BiotechnologyHealth Technology Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member | |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
ACTICOR BIOTECH SAS | Biotechnology | Director/Board Member | |
Ncardia SA
Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Opdorp Finance BV
Opdorp Finance BV Investment Trusts/Mutual FundsMiscellaneous Opdorp Finance BV operates as a finance industry. The private company is based in Antwerp, Belgium. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
AQ Partners SRL | Corporate Officer/Principal | ||
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Founder Chairman Chief Executive Officer | |
Heran Partners BVBA
Heran Partners BVBA Investment ManagersFinance Heran Partners BVBA is a venture capital and private equity firm founded in 2020 by Annie Vereecken, Katleen Vandersmissen, Joris Mortelmans and Herman Verrelst. The firm is headquartered in Antwerp, Belgium. | Investment Managers | Founder | |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | Biotechnology | Director/Board Member | |
Laboratoria Wolfs NV
Laboratoria Wolfs NV Pharmaceuticals: MajorHealth Technology Laboratoria Wolfs NV is a pharmaceutical and Belgian nutraceutical product manufacturing company founded in 1968. The private company is based in Zwijndrecht, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Veran NV
Veran NV RestaurantsConsumer Services Veran NV operates fast food restaurants. The private company is based in Antwerp, Belgium. The Belgian company was founded in 1980. Annie Vereecken has been the CEO of the company since 2017. | Restaurants | Chief Executive Officer | |
Ncardia Holding SA
Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | Biotechnology | Director/Board Member | |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Agricells SA
Agricells SA BiotechnologyHealth Technology Agricells SA is a Belgian company that specializes in research and development for agriculture using biosolutions such as biocontrol, biostimulant, and biofertilizer. The company is based in Marche-en-Famenne, Belgium. The company focuses on innovation, greentech, and biotechnologies in the field of agriculture. Agricells was founded in 2020 by Maxence Semacoy Albertini and Vincent Vandamme, with Maxence Semacoy Albertini serving as the CEO since 2020. | Biotechnology | Director/Board Member | |
THERAtRAME SA
THERAtRAME SA BiotechnologyHealth Technology THERAtRAME SA is a drug discovery start-up company based in Liege, Belgium. The Belgian company aims to become a leader in the development and positioning of novel cancer therapies by exploring new target areas to develop innovative cancer therapies. THERAtRAME's discovery platform integrates unique sets of technologies to discover, develop, and position new drugs to beat reluctant cancers. The company exploits the latest scientific discoveries highlighting the unexpected importance of trna epitranscriptomics dynamics in cancer. THERAtRAME is looking for a drug discovery assay developer leader to join their team. The company was founded by Francesca Rapino, Pierre Close, and has a team of experienced professionals with backgrounds in life sciences, medico-marketing, and biotech venture creations. | Biotechnology | Chairman | |
A Q Invest SRL | Corporate Officer/Principal | ||
Peptisyntha SA
Peptisyntha SA Chemicals: SpecialtyProcess Industries Peptisyntha SA manufactures and supplies small to commercial scale cGMP peptide APIs for pharmaceutical and biotech companies. The firm offers solid-phase peptide synthesis, liquid-phase peptide synthesis, hybrid strategies, complex peptides and peptidomimetics, peptide-conjugations, cyclic peptides and multiple disulfide bridges peptides, short peptides, and arginine-rich peptides. It serves customers worldwide. Peptisyntha was founded in 1987 and is headquartered in Brussels, Belgium. | Chemicals: Specialty | Chief Executive Officer |
Statistieken
Internationaal
België | 40 |
Luxemburg | 3 |
Frankrijk | 3 |
Nederland | 3 |
Verenigde Staten | 3 |
Sectoraal
Health Technology | 21 |
Consumer Services | 8 |
Commercial Services | 7 |
Finance | 6 |
Technology Services | 3 |
Operationeel
Director/Board Member | 104 |
Private Equity Investor | 20 |
Chief Executive Officer | 20 |
Corporate Officer/Principal | 16 |
Founder | 14 |
Sterkste connecties
Insiders | |
---|---|
Rudi Mariën | 31 |
Alain Parthoens | 29 |
Martin de Prycker | 21 |
Michel Allé | 20 |
Els Hubloux | 11 |
Philippe Stas | 10 |
Marie Bouillez | 9 |
Annie Vereecken | 8 |
Marc Zabeau | 7 |
Sofie Baeten | 7 |
Pierre Detrixhe | 5 |
Fasha Mahjoor | 5 |
Jean van Nuwenborg | 5 |
Johan Devenyns | 4 |
Steven Leuridan | 2 |
- Beurs
- Insiders
- Danny Gonnissen
- Bedrijfsconnecties